• Vaccine Name: B16 Vaccine adjuvanted by Loxoribine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0001380
• Type: Live, attenuated vaccine
• Status: Research
• Antigen: Irradiated B16 cells (Pope et al., 1994).
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001300
• Preparation: Loxoribine can be used to promote inhibition of B16 metastasis (Pope et al., 1994).
• Immunization Route: Intraperitoneal injection (i.p.)
• Description: This vaccine has been used in clinical trials involving melanoma. (Pope et al., 1994)

Mouse Response

• Host Strain: C57BL/6J
• Vaccination Protocol: Mice were injected i.p. with 0.5 ml irradiated cells 21 and 14 days before challenge, and were injected with loxoribine prior to challenge (Pope et al., 1994).
• Challenge Protocol: Mice were challenged i.v. with live B16 cells (Pope et al., 1994).
• Efficacy: Mice treated with loxoribine had significant inhibition of tumor growth following challenge with live B16 cells (Pope et al., 1994).